Venus Remedies Gets 75% of FY25 PLI Incentive Under Pharma Scheme
Mumbai: Venus Remedies Limited has received its second incentive disbursement under the Government of India's Production Linked Incentive (PLI) Scheme for Pharmaceuticals, amounting to 75 percent of the total incentive eligible for FY 2024-25.
The disbursement follows the company’s fulfilment of the investment, production and sales criteria stipulated under the scheme. Venus Remedies is among the pharmaceutical companies approved under the PLI 2.0 framework.
The incentives are expected to support manufacturing scale-up and technology upgrades in line with the objectives of the PLI scheme, which aims to strengthen domestic pharmaceutical manufacturing and reduce import dependence.
Commenting on the development, Saransh Chaudhary, President, Global Critical Care, Venus Remedies Limited, and CEO, Venus Medicine Research Centre, said the PLI disbursements would support capacity expansion and investments in manufacturing and technology aligned with national healthcare and industrial priorities.
Launched under the Atmanirbhar Bharat initiative, the Government of India’s PLI scheme is aimed at boosting domestic investment, increasing production, and improving global competitiveness across key manufacturing sectors, including pharmaceuticals. The scheme has a total outlay of ₹15,000 crore for the period from 2020–21 to 2028–29.
According to government data, India has moved from being a net importer of bulk drugs, with a deficit of ₹1,930 crore in FY 2021–22, to recording a surplus of ₹2,280 crore in FY 2024–25. Cumulative pharmaceutical sales under the PLI scheme crossed ₹2.66 lakh crore in its first three years, including exports of ₹1.70 lakh crore, with domestic value addition reported at 83.70 percent as of March 2025.
Panchkula-based Venus Remedies Ltd is engaged in the manufacture of fixed-dosage injectable formulations and operates manufacturing facilities in India and Germany. The company has a presence across multiple international markets and holds approvals from several global regulatory agencies.
Venus Remedies also operates a research division, the Venus Medicine Research Centre, which focuses on the development of antibiotics and therapies addressing antimicrobial resistance.
